137 related articles for article (PubMed ID: 38272014)
1. One-Bag 8-Step Ferric Carboxymaltose Desensitization Protocol for Patients with a History of Hypersensitivity Reactions to Iron Preparations.
Özden Ş; Tepetam FM; Atik Ö
Int Arch Allergy Immunol; 2024; 185(5):449-455. PubMed ID: 38272014
[TBL] [Abstract][Full Text] [Related]
2. A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia.
Montandon SV; Fajt ML; Petrov AA
Curr Drug Saf; 2016; 11(2):145-8. PubMed ID: 26647917
[TBL] [Abstract][Full Text] [Related]
3. Retrospective cohort study comparing the adverse reactions and efficacy of intravenous iron polymaltose with ferric carboxymaltose for iron deficiency anemia.
Gilmartin CE; Hoang T; Cutts BA; Leung L
Int J Gynaecol Obstet; 2018 Jun; 141(3):315-320. PubMed ID: 29498039
[TBL] [Abstract][Full Text] [Related]
4. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
[TBL] [Abstract][Full Text] [Related]
5. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
6. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions.
Bager P; Hvas CL; Dahlerup JF
Br J Clin Pharmacol; 2017 May; 83(5):1118-1125. PubMed ID: 27859495
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from 2008 to 2017.
Durup D; Schaffalitzky de Muckadell P; Strom CC
Expert Rev Hematol; 2020 May; 13(5):557-564. PubMed ID: 32129113
[No Abstract] [Full Text] [Related]
8. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
Pollock RF; Biggar P
Expert Rev Hematol; 2020 Feb; 13(2):187-195. PubMed ID: 31928094
[No Abstract] [Full Text] [Related]
9. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis.
Shin HW; Go DY; Lee SW; Choi YJ; Ko EJ; You HS; Jang YK
Medicine (Baltimore); 2021 May; 100(20):e24571. PubMed ID: 34011020
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
[TBL] [Abstract][Full Text] [Related]
11. Desensitization in Iron Product Allergy.
Di Girolamo A; Albanesi M; Loconte F; Di Bona D; Caiaffa MF; Macchia L
Acta Haematol; 2020; 143(5):496-499. PubMed ID: 32182610
[TBL] [Abstract][Full Text] [Related]
12. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
13. Interventions for treating iron deficiency anaemia in inflammatory bowel disease.
Gordon M; Sinopoulou V; Iheozor-Ejiofor Z; Iqbal T; Allen P; Hoque S; Engineer J; Akobeng AK
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013529. PubMed ID: 33471939
[TBL] [Abstract][Full Text] [Related]
14. Intravenous ferric carboxymaltose for iron deficiency anemia in dialysis patients: Effect of a new protocol adopted for a hemodialysis limited assistance center.
Gobbi L; Scaparrotta G; Rigato M; Cattarin L; Qassim L; Carraro G; Rossi B; Calò LA
Ther Apher Dial; 2020 Dec; 24(6):642-647. PubMed ID: 32154642
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study.
Ikuta K; Ito H; Takahashi K; Masaki S; Terauchi M; Suzuki Y
Int J Hematol; 2019 Jan; 109(1):50-58. PubMed ID: 30194568
[TBL] [Abstract][Full Text] [Related]
17. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
[TBL] [Abstract][Full Text] [Related]
18. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.
Adkinson NF; Strauss WE; Macdougall IC; Bernard KE; Auerbach M; Kaper RF; Chertow GM; Krop JS
Am J Hematol; 2018 May; 93(5):683-690. PubMed ID: 29417614
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review.
Qassim A; Mol BW; Grivell RM; Grzeskowiak LE
Aust N Z J Obstet Gynaecol; 2018 Feb; 58(1):22-39. PubMed ID: 28921558
[TBL] [Abstract][Full Text] [Related]
20. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.
Toblli JE; Angerosa M
Drug Des Devel Ther; 2014; 8():2475-91. PubMed ID: 25525337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
